Background / Aims: Bronchiolitis imposes the largest health care burden on non-elective paediatric hospital admissions worldwide, with up to 15% of cases requiring admission to ICU. Numerous studies have investigated the roles of steroids, salbutamol, adrenalin and inhalation of hypertonic saline. All of which failed to show benefit to length of stay, reduction in ICU admissions or intubation frequency. Current management is focused on oxygen therapy for hypoxia, respiratory support and maintenance of hydration. Respiratory support traditionally has been the domain of ICU settings provided through simple oxygen delivery, non-invasive ventilation with CPAP and finally intubation and ventilation. This has a huge impact on health cost and can result in greater incidence of adverse events.
High Flow Nasal Cannula therapy (HFNC) has emerged as a new method to provide humidified air flow to deliver a non-invasive form of positive pressure support with titratable oxygen fractions. Currently there is a lack of evidence of HFNC therapy use in bronchiolitis. Aim is to compare the different therapies by looking at failure of treatment defined as need to escalate respiratory support and admissions to ICU. By reviewing length of stay, health cost, length of treatment and measurement of adverse events
Methods:Non Blinded multicentre, randomized controlled trial comparing respiratory support and oxygen delivery via HFNC therapy versus standard sub nasal oxygen therapy in infants up to 12 months of age admitted to hospital with Bronchiolitis. It involves 17 hospitals in Australia and New Zealand with a target sample size of 1414.
Results:No results yet, started in July 2015 and is over 3 years.
Counties Manukau Health